References
- Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356: 881–7.
- Mignotte H, Lasset C, Bonadona V, Lesur A, Luporsi E, Rodier JF et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 1998; 76: 325–30.
- Deligdisch L, Kalir T, Cohen CJ, de Latour M, Bouedec GL, Penault-Llorca F. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 1999; 78: 181–6.
- Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994; 13: 248–58.
- Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994; 343: 1318–21.
- Timmerman D, Deprest J, Vergote I. Tamoxifen-induced endometrial polyp. N Engl J Med 1996; 336: 1389–90.
- Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994; 47: 827–33.